2025 Sponsors

DIAMOND SPONSOR

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our teams across the world strive to transform the practice of medicine, turning the impossible into the possible for patients. We provide potentially life-changing treatments and the protection of life-saving vaccines to millions of people, and affordable access to our medicines in some of the world’s poorest countries.

PLATINUM SPONSORS

Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetic and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in healthcare in approximately 80 countries.

Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach more than 750 million people globally and we are finding innovative ways to expand access to our latest treatments. About 105,000 people of more than 140 nationalities work at Novartis around the world. For more information visit: www.novartis.com

We are focused on creating genuinely innovative medicines and improving access to them. In this way, we deliver the greatest benefit to patients, healthcare systems and societies globally. We have three priorities designed to deliver our growth through innovation strategy. Accelerate Innovative Science: Accelerating the next wave of new molecular entities, building our capabilities in immunology and rare diseases, pursuing new scientific modalities and driving R&D productivity Deliver Growth and Therapy Area Leadership: Meeting our growth and profitability goals through successful innovation and commercial excellence, as well as completing the Alexion acquisition Be a Great Place to Work: Contributing to the enterprise and to society, with a focus on inclusion and diversity, lifelong learning, improving access to healthcare, environmental protection, and ethics and transparency, as well as delivering our Ambition Zero Carbon program. Inspired by our Values and what science can do, we are focused on accelerating the delivery of life-changing medicines that create enduring value for patients and society. We are committed to operating in a way that recognizes the interconnection between business growth, the needs of society and the limitations of our planet.

GSK is a science-led global healthcare company on a mission to research, develop, manufacture and market innovative medicines and vaccines to unite science, technology and talent to get ahead of disease together. GSK has a 300-year global legacy, and for more than 65 years has been operating, employing and investing in the Gulf Cooperation Council region. We aim to positively impact the health of 2.5 billion people over the next 10 years. Our bold ambitions for patients are reflected in new commitments to growth and a step-change in performance. We are a company where outstanding people can thrive.

SILVER SPONSORS

NewBridge Pharmaceuticals, headquartered in Dubai, UAE, is a regional specialty company with a comprehensive pharmaceutical platform of services and expertise, established to bridge the access gap and partner with global pharma and biotech companies to in-license and commercialize U.S. FDA or EMA approved innovative therapeutics that address unmet medical needs into the Middle East and North Africa (MENA) regions.

Biologix helps multinational pharmaceutical manufacturers bring innovative drugs to market in the Middle East / North Africa (MENA) region. Positioned across 17+ key strategic locations in the Gulf Cooperation Council (GCC), Egypt, North Africa and the Levant, we are pioneers in regional distribution and promotion of innovative products and solutions for difficult-to-treat diseases. A privately owned pharmaceutical company organized under the laws of the United Arab Emirates (UAE), Biologix provides end-to-end solutions from the preregistration phase all the way to commercial-scale market access and risk management. Incorporated in the Dubai Airport Free Zone in September 2002, Biologix traces its history back to 1997. We were among the first organizations to recognize the need for long-term strategic partnerships in the MENA region, and today we connect pharma leaders around the world with integrated direct-access healthcare approaches.

Inmunotek is an European pharmaceutical company based in Alcalá de Henares – Madrid – (Spain) that researches, develops, manufactures and markets products in the field of Allergy and Immunology for the diagnosis and treatment of allergic and other immune-based diseases in human and veterinary medicine. Inmunotek is made up by a multidisciplinary team of professionals comprising pharmacists, doctors, biologists, chemists and engineers. It includes specialists in immunology, allergy and microbiology together with technicians specialized in various production and control areas as well as staff dedicated to R&D and technological innovation. Inmunotek has GMP facilities with fully equipped labs for Production and Quality Control. It has also facilities for producing raw materials including biological products, such as bacteria, fungi and mites.

Stallergenes Greer is a fully integrated global biopharmaceutical company, specializes in the diagnosis and treatment of allergies through the research, development and commercialization of AIT products and services for respiratory and food allergies. Stallergenes Greer is a leader in its field with more than a century of expertise in allergies and allergen immunotherapy (AIT).

Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale, currently supplying high-quality medicines to approximately 1 billion patients around the world annually and touching all of life's moments, from birth to the end of life, acute conditions to chronic diseases. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world's most enduring health challenges, access takes on deep meaning at Viatris. We are headquartered in the U.S. Learn more at viatris.com and investor.viatris.com, and connect with us on LinkedIn, Instagram, YouTube and X (formerly Twitter).

At Genpharm, our mantra is clear – Bringing Cures To MENAT Patients. Genpharm is a pharmaceutical market access company focused on niche therapeutics and diagnostics for rare diseases and specialty. We provide fast and sustainable market access solutions into the MENAT (Middle East, North Africa, and Turkey) region to our strategic partners. We act as the exclusive regional commercial partner for pharmaceutical pioneers in the MENAT. Our expertise is maintained through our crossfunctional departments such as Medical Affairs, PV, Regulatory, Quality, Logistics, and more. We provide strategic advice and solutions on Business Development opportunities as well as pathway for companies evaluating their entry into MENAT. We are proud to be the first company to successfully introduce gene therapy in the MENAT region.

We are an independent, research-based pharmaceutical company We are a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society What we stand for - Our people are united worldwide with strong core values and a common vision Position and views - We support public policies that promote the discovery of innovative medicines and better accessibility to those who need them Our heritage - From humble beginnings in the basement of the Copenhagen LEO Pharmacy, we have now grown into a global leader in dermatology Our governance - Our proactive and transparent corporate governance structure promotes sustainable business behavior and long-term value creation

Driven by Our Promise. It began with a promise. CSL Behring's parent company, CSL, was formed more than 100 years ago to save lives using the latest technologies. In the century since, CSL Behring has grown into a global biotechnology leader, driven by that same promise to save and improve lives. We offer the broadest range of quality plasma-derived and recombinant therapies in our industry. Our ability to innovate and deliver life-saving medicines for patients with rare disease and other unmet medical needs around the world has earned us a reputation for always putting patients first. We are CSL Behring and we are driven by our promise.

EXHIBITORS

We are an international group based in Parma, research-oriented, with over 85 years of experience, present in 30 countries. The Chiesi Group researches, develops and markets innovative drugs in three specific areas: AIR (products and services in the respiratory field, from infants to adults), RARE (innovative solutions and personalized services to improve the quality of life of patients with rare and ultra-rare diseases) and CARE (products and services to support specialist care, personal care and well-being). Since 2019 we are a certified B Corp, while, in 2018, we changed our legal status to a Benefit Company, realizing the desire to measure our impact on society and the environment, combining the need to generate value for the business to acting as a positive force for the community in which we live.

New Country Healthcare (NCH) was founded in 1978 as Country Pharmacy and evolved to New Country Healthcare in 1990, NCH today is a leader in the healthcare sector, with a rich portfolio that includes over 1500 products manufactured in United States, Canada, Europe, Asia and Middle East. NCH started with a vision of a healthier community by our Chairman Dr. Ghazi Al Koudsi, a UAE board certified pharmacist and consultant to governing agencies. With hard work and dedication, NCH has not only kept their promise to the community but, has also stayed true to the vision of our chairman who inspires every member of the NCH family to give their best every day.